Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information

Chao Han¹, Lina Zhu², Xiang Liu¹, Shuai Ma¹, Yi Liu¹ and Xiaoying Wang¹*

Abstract
The differential diagnosis of abnormalities in the prostate is broad, covering common (acinar adenocarcinoma, benign prostatic hyperplasia, chronic prostatitis, hemorrhage, cysts, calcifications, atrophy and fibrosis) and less common conditions (tumors other than acinar adenocarcinoma, granulomatous prostatitis containing tuberculosis, abscesses and other conditions, and idiopathic disorders such as amyloidosis and exophytic benign prostatic hyperplasia). Recent advances in magnetic resonance imaging (MRI) of the prostate gland and imaging guidelines, such as the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1), have dramatically improved the ability to distinguish common abnormalities, especially the ability to detect clinically significant prostate cancer (csPCa). Overlap can exist in the clinical history and imaging features associated with various common/uncommon prostate abnormalities, and biopsy is often required but is invasive. Prostate abnormalities can be divided into two categories: category 1, diseases for which PI-RADS scores are suitable for use, and category 2, diseases for which PI-RADS scores are unsuitable for use. Radiologists must have an intimate knowledge of other diseases, especially uncommon conditions. Past relevant history, symptoms, age, serum prostate-specific antigen (PSA) levels, MRI manifestations, and the applicability of the PI-RADS assessment should be considered when diagnosing prostate abnormalities.

Keywords: Prostate, Magnetic resonance imaging, Uncommon prostatic diseases

Key Points
- Prostate abnormalities can be divided into two categories, PI-RADS suitable and PI-RADS unsuitable.
- Radiologists must have an intimate knowledge of uncommon prostate abnormalities.
- Granulomatous prostatitis adds a diagnostic challenge as it usually mimics PCA radiologically.
- Most sarcomas appear as well-circumscribed masses with a complete or incomplete pseudocapsule.

Background
Diseases of the prostate make up a large proportion of male urologic diseases. In the clinic, individuals usually visit the hospital with overlapping symptoms of prostatic diseases or elevated serum prostate-specific antigen (PSA) levels. Currently, advances in multiparametric magnetic resonance imaging (mpMRI) of the prostate gland and the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1) have remarkably improved the ability to detect and stage clinically significant prostate cancer (csPCa) [1–4].

PI-RADS v2.1 suggests the use of the mpMRI protocol, including T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) maps and dynamic contrast-enhanced (DCE) imaging, to provide both imaging and functional information of the prostate. In addition, radiologists use...
PI-RADS v2.1 assessment categories, a 5-point scale from PI-RADS 1 to 5, to express the probability of the presence of csPCa for each lesion in the prostate gland [3]. Therefore, PI-RADS v2.1 is widely applied in the clinic to distinguish csPCa from benign prostatic hyperplasia (BPH), chronic prostatitis, or other common prostatic diseases. However, unusual diseases involving the prostate, such as uncommon prostatic neoplasms, are classified into multiple classes. As a result of their relative rarity and diverse imaging presentations [5], many radiologists might not be familiar with their characteristics or situations in which the use of the PI-RADS assessment is appropriate.

Therefore, in this article, prostatic diseases are divided into two categories: category 1, diseases for which the PI-RADS assessment is suitable for use, and category 2, diseases for which PI-RADS assessment is not suitable for use. The characteristics of common prostatic diseases are simply reviewed, followed by a focus on the characteristics of unusual prostatic diseases. In addition, we summarize the clinical MRI diagnostic workflow for prostatic diseases.

Classification of prostatic diseases

Common diseases of the prostate include acinar adenocarcinoma, BPH, chronic prostatitis, hemorrhage, cysts, calcifications, atrophy and fibrosis. Uncommon diseases of the prostate include tumors other than acinar adenocarcinoma, granulomatous prostatitis containing tuberculosis, abscesses and so on, and idiopathic disorders such as amyloidosis and exophytic BPH.

Many conditions that yield abnormal signals within the prostate, including hemorrhage, cysts, calcifications, atrophy and fibrosis, are benign and highly recognizable on mpMRI [3]. In addition to these benign signal abnormalities and based on the applicability of PI-RADS assessment, we divide other focal signal abnormalities involving the prostate into two categories according to the patient’s age, serum PSA level, symptoms and mpMRI findings: category 1, diseases for which the PI-RADS assessment is suitable for use, and category 2, diseases for which the PI-RADS assessment is not suitable for use. Category 1 includes prostate cancer (PCa), typical BPH in the transitional zone (TZ), and some types of prostatitis/granulomatous prostatitis, which overlap in terms of clinical and mpMRI findings, while category 2 includes tumors except for PCa, exophytic BPH nodules, and some types of granulomatous prostatitis (abscesses and tuberculosis), for which PCa may be excluded according to the clinical and MRI findings.

Common prostatic diseases other than typical benign lesions

Common prostatic diseases other than typical benign lesions, such as acinar adenocarcinoma, BPH and prostatitis, are usually inert or chronic, with varying degrees of elevated serum PSA levels or disturbing symptoms such as lower urinary tract symptoms (LUTS), and interfere with the quality of life as a long-term problem for males, particularly elderly males, as BPH and prostate cancer are age-related conditions [6]. PSAs are proteinases produced mainly in the epithelial cells of the prostate [7]. When various factors cause destruction of the epithelial cells or the blood-epithelial barrier, a substantial increase in PSA secretion from tumor cells, or increasing entry of PSAs into the blood, serum PSA levels are increased.

PCa is one of the most common groups of malignancies occurring in the male population after lung cancer [8], among which acinar adenocarcinoma is the most common malignancy observed. On MRI, csPCa presents with homogeneous and moderate hypointensity on T2WI, hyperintensity on high b-value DWI, a low ADC, and early enhancement, without capsules and easily forming extraprostatic extensions (EPEs). These findings result in a PI-RADS 4–5 classification.

BPH is the fifth most prevalent non-cancer-related disorder among 50-year-old or elderly men [9]. By the age of 60, the prevalence of BPH is 50%, and it increases to 80% by the age of 80. BPH tissue produces PSA and primarily arises in the TZ. BPH consists of glandular hyperplasia and stromal hyperplasia. Predominantly glandular BPH nodules exhibit moderate hyperintensity on T2WI with hypointense capsules, while predominantly stromal nodules present hypointensity on T2WI. A mixture of stromal and glandular hyperplasia may appear as band-like areas and/or encapsulated round nodules with circumscribed or encapsulated margins. Many BPH nodules display a mixture of signal intensities on T2WI and may be remarkably enhanced on DCE imaging [3]. The PI-RADS assessment is suitable for use and PI-RADS scores of 1–2 may be assigned to typical BPH.

Chronic prostatitis is often subclinical and presents as an immune infiltrate. On T2WI and ADC maps, chronic prostatitis often presents with decreased signals that are band-like, wedge-shaped, or diffuse in the peripheral zone (PZ). On DCE imaging, they may exhibit early enhancement. The PI-RADS assessment is suitable for use and a PI-RADS score of 2 may be assigned to typical chronic prostatitis.
Uncommon prostatic diseases
BPH nodules outside the TZ

Although BPH develops in the TZ, hyperplastic prostatic nodules may also be found in the PZ or central zone (CZ). Peripheral hyperplastic nodules comprise up to 18.5% of prostate specimens with palpable and/or ultrasonographically hypoechoic focal lesions [10], and less than 10.0% of ultrasonographically hypoechoic focal nodules located in the PZ of the prostate are histologically confirmed as BPH [11, 12].

Some authors believe that BPH arises in the TZ, but a few BPH nodules can be exophytic or extrude into the PZ or CZ. However, Jie Tang et al. indicated that some BPH nodules in the PZ originate from the PZ, and the formation of these nodules may be modulated in a different manner than those that form in the TZ because the relative expression of proteins involved in the regulation of prostate proliferation and apoptosis differs between PZ and TZ hyperplastic nodules [13].

PZ and TZ hyperplastic nodules are similar regarding patient age, PSA level, prostate volume and nodule size [13, 14]. BPH nodules outside the TZ are usually well-circumscribed lesions with an ovoid or round shape and a smooth surface on MRI, and the size of the nodule may also increase with the progress of BPH in the TZ (Fig. 1). In this situation, the PI-RADS assessment is not suitable for use.

Granulomatous prostatitis

Recently, radiologists’ knowledge of granulomatous prostatitis has improved because of an increase in the prevalence of the disease due to an increase in the implementation of various surgical interventions, such as transurethral resection of prostate (TURP) and needle biopsy procedures. Granulomatous prostatitis is an unusual and benign inflammatory condition of the prostate classified based on etiology and histopathology into the following types: idiopathic (nonspecific), infective, iatrogenic (after surgical operation), malakoplakia, and cases associated with systemic granulomatous diseases and allergy [15]. Among these conditions, nonspecific granulomatous prostatitis is the most common accounting for 45–77.7% of cases, for which autoimmunity has been recognized as a key factor in the pathogenesis [16, 17]. In total, granulomatous prostatitis accounts for approximately 3.3% of all benign inflammatory lesions of the prostate and less than 2% of all prostatic specimens, including prostatic biopsies, TURP chips, and radical prostatectomies [15, 17].

Clinically, granulomatous prostatitis may present with symptoms including irritation and LUTS, with or without hematuria, fever and chills, and is frequently associated with transiently increased serum PSA levels, which may decrease with the resolution of the inflammation [18]. The age of onset ranges from 18 to 86 years, with a mean age of 70 years [15, 17].

On mpMRI, granulomatous prostatitis strongly mimics PCa regardless of whether it is diffuse (Fig. 2) or focused (Fig. 3), with hypointensity on T2WI and obviously restricted diffusion on DWI and ADC maps, and presents earlier or contemporaneous with the enhancement of adjacent normal prostatic tissues on DCE imaging [19] (Figs. 2d and 3c). In addition, capsular bulges or capsular irregularities suspected of early extracapsular extension can also be observed (Fig. 2). The majority of lesions of granulomatous prostatitis confirmed on fusion-targeted biopsies are assigned a PI-RADS score of 4 or 5 [20]. Interestingly, some cases of diffuse granulomatous prostatitis may present with hyperintense signals on T1WI [21] (Fig. 4b). The diagnosis of granulomatous prostatitis is also challenging because it usually mimics PCa both clinically and radiologically, and the PI-RADS assessment may be used unavoidably; hence the diagnosis is only possible by performing a histopathological examination.
Central necrosis can occur in several cases of granulomatous prostatitis. Abscesses may form by the combined effect of central inflammatory cells, proteins, cellular debris, and water molecules bound to macromolecules [22] and are more common in infective than in other types of granulomatous prostatitis. Infective granulomatous prostatitis can be caused by bacteria (such as *E. coli*, *Staphylococcus* species, and *Mycobacterium tuberculosis*), viruses (*herpes zoster*), fungi (*Cryptococcus*, *Candida*, *Aspergillus*), or *Treponema pallidum* [23, 24]. Typical signs and symptoms may include fever, chills, urinary frequency and urgency, suprapubic pain, dysuria, and hematuria. Urine examination usually reveals pus cells.

DWI and ADC maps demonstrate the highly viscous internal contents of abscesses, which are surrounded by granulomatous infiltration that appears as low T2 signal intensity, restricted diffusion, and moderate...
enhancement. The features on MRI are typical (Fig. 5); the interior of the central necrosis presents with hyperintensity on T2WI, hyperintensity on high b-value DWI, and low ADC, and the exterior demonstrates rim enhancement [16, 23]. PI-RADS may not be applicable in these situations. Nevertheless, MRI is useful for evaluating the prevalence of occult caseous abscesses and for follow-up after treatment.

Prostate tuberculosis

Tubercular involvement of the prostate gland may cause infectious granulomatous prostatitis, also known as prostate tuberculosis, which is caused by M. tuberculosis (via hematogenous spread or direct extension from adjacent organs). Some patients with prostate tuberculosis have a prior history of intravesical bacillus Calmette-Guérin (BCG) therapy for urothelial carcinoma [23] or present by tuberculosis in other organs of genital system (Fig. 6a) or other systems. Prostate tuberculosis is rare; only 22% of extrapulmonary tuberculosis cases affect the genitourinary system, and prostate tuberculosis is observed in only 2.7% of patients with genitourinary tuberculosis [25]. Serum PSA levels may be normal or increased. Symptoms are nonspecific, including dysuria with increased frequency and urgency. The MRI appearances of tubercular granulomatous prostatitis are varied. Solid nodules (isolated or multifocal) may be markedly hypointense on T2WI (Fig. 6b) and infrequently hyperintense on T1WI, which may be due to the presence of paramagnetic substances, such as macrophage-laden oxygen-free radicals, in which reduce the T2 and T1 values [26]. Compared with the normal PZ, diffuse lesions usually show a diffuse, low T2 signal intensity [27] and equal or low T1 signal intensity but may be accompanied by slightly higher interior T1 signal intensity [26]. Nonnecrotic lesions may appear with moderate hyperintensity, isointensity or hypointensity on DWI (Fig. 6d). When central necrosis (caseation) occurs in tubercular granuloma, cystic areas appear. The necrosis displays various intensities on DWI, which can be hyperintense, isointense or hypointense due to differences in constituents and concentrations. Nevertheless, typical
necrotic tubercular granulomatous prostatitis appears as abscesses, in which the caseation appears as hyperintensity on T2WI, hyperintensity on DWI, a low ADC, and a lack of enhancement [23]. The PI-RADS assessment may not be applicable in most cases of prostate tuberculosis.

**Prostatic neoplasms**

A wide variety of tumors, both benign and malignant, occur involving the prostate. The 2016 World Health Organization classification of tumors of the prostate (Table 1) categorizes them as follows: epithelial, neuroendocrine, mesenchymal, hematolymphoid, miscellaneous and metastatic [28]. More than 95% of malignant tumors of the prostate are acinar adenocarcinomas [29]. Unusual tumors of the prostate are classified into multiple types although they constitute a small percentage of tumors.

**Intraductal carcinoma**

Intraductal carcinoma of the prostate (IDC-P) is a newly recognized entity of epithelial tumor in the 2016 WHO classification, which is used to describe intra-acinar and/or intraductal neoplastic epithelial proliferation. Although IDC-P has some features of high-grade prostatic intraepithelial neoplasia, it presents with much greater architectural and/or cytological atypia [28]. The prevalence of IDC-P is 13–17% among radical prostatectomy (RP) specimens [30] and the incidence of IDC-P with concomitant, invasive adenocarcinoma on biopsy is less than 25%, while isolated IDC-P occurs in only less than 0.3% of biopsies [31]. The extent of IDC-P is a well-known adverse independent prognostic factor regardless of treatment and can be an important prognostic factor for the outcome [32].

Although not assigned a Gleason grade, IDC-P is usually associated with invasive prostate carcinoma, typically with high-grade, high-stage patterns. Therefore, the MRI appearances may present as a typical csPCa of PI-RADS category > 3 with/without EPE (Fig. 7). Currin S et al. reported that the presence of intraductal spread of PCa lowers ADC values in intermediate-risk Gleason-score 7 tumors, and the PI-RADS v2 assessment category is also higher in IDC-P tumors [33].

**Ductal adenocarcinoma**

Ductal adenocarcinoma of the prostate is a rare subtype and ranks second in frequency among prostate epithelial tumors. Mixed acinar and ductal adenocarcinoma account for 5% of all PCa cases, whereas pure ductal adenocarcinoma accounts for less than 1% [34]. Ductal adenocarcinoma shows more aggressive behavior and has a worse prognosis than conventional prostatic acinar adenocarcinoma.

Ductal adenocarcinoma demonstrates similar clinical features as prostatic acinar adenocarcinoma. However, serum PSA levels may not be elevated early, as ductal adenocarcinoma originates from the ductal epithelium, which poorly secretes PSA early, only when the tumor spreads or destroys the blood-epithelial barrier.

On MRI, ductal adenocarcinoma may also present as prostatic acinar adenocarcinoma [35], and the PI-RADS assessment is applicable. However, in a few cases, ductal adenocarcinoma with/without acinar adenocarcinoma presents with a cystic/multicystic growth pattern (Fig. 8), which is due to occlusion of the prostatic duct and induction of cystic dilation, intracancerous tissue hemorrhage or central necrosis of the cancer tissue [36, 37]. The presence of cysts with thick walls or mural nodules with restricted diffusion may be malignant signs distinguishing them from cystadenoma.
Urothelial carcinoma

Urothelial carcinoma of the prostate can occur primarily from the prostate gland, arising from the prostatic ducts or acini and accounting for less than 5% of all prostate carcinomas [38], or synchronously with urothelial carcinoma of the bladder or urethra. It primarily manifests in middle-aged men, who are typically younger than prostatic adenocarcinoma patients. Serum PSA values for this disease are usually within the normal range.

On MRI, urothelial carcinoma of the prostate may present as a mass similar to urothelial carcinomas of the bladder or urethra. The presence of synchronous tumors elsewhere in the genitourinary system also increases the possibility of urothelial carcinoma. The PI-RADS assessment is not suitable for use. Urothelial carcinoma exhibits a highly aggressive biological behavior and has a poor prognosis with a strong tendency of local recurrence (Fig. 9) and distant metastasis.

Prostatic stromal tumors

Prostatic stromal tumors arising from specialized prostatic stroma have been subdivided into stromal tumors of uncertain malignant potential (STUMPs) and prostatic stromal sarcomas (PSSs), which occur at a peak incidence in the sixth and seventh decades of life [39, 40]. According to the 2016 WHO classification of tumors of the prostate, STUMPs and PSSs are classified as mesenchymal tumors [28], rather than the independent classification of prostatic stromal tumors in the 2004 WHO classification.

PSSs have been reported to affect a slightly younger population than STUMPs, and approximately half of all reported cases of PSSs occur before the age of 50 years [41, 42]. Prostatic stromal tumors are rare, and PSSs account for approximately 0.1% of primary prostate malignancies in adults [43]. The most common symptoms of presented by patients with both STUMP and PSS are chronic LUTS, but the symptoms are not specific [39, 44].

Upon a histological examination, STUMPs and PSSs are differentiated according to the degree of cellularity and the presence of mitotic figures, necrosis, and stromal overgrowth [39]. Necrosis, cystic changes and hemorrhage are common in PSSs (Figs. 10 and 11d) because of their high malignancy and rapid growth, which may help to distinguish more aggressive PSSs from more benign variants of STUMP on MRI. MRI also helps reveal enlarged pelvic lymph nodes (Fig. 10). On MRI, the most common manifestations of STUMPs and PSSs are a rim-like hypointense “capsule” on T2WI, which is complete or incomplete (Figs. 11a, 12a and 13a). However, neither STUMPs nor PSSs contain fibrous capsules on histopathologic examination, so

| Table 1 World Health Organization classification of tumors of the prostate |
|-----------------------------------------------|
| **Category/Tumor**                          |
| **Epithelial tumors**                        |
| Glandular neoplasms                          |
| Acinar adenocarcinoma                        |
| Prostatic intraepithelial neoplasia, high-grade |
| Intraductal carcinoma                        |
| Ductal adenocarcinoma                        |
| Urothelial carcinoma                         |
| Squamous neoplasms                           |
| Adenosquamous carcinoma                      |
| Squamous cell carcinoma                      |
| Basal cell carcinoma                         |
| **Neuroendocrine tumors**                    |
| Adenocarcinoma with neuroendocrine differentiation |
| Well-differentiated neuroendocrine tumor      |
| Small cell neuroendocrine carcinoma          |
| Large cell neuroendocrine carcinoma          |
| **Mesenchymal tumors**                       |
| Stromal tumor of uncertain malignant potential |
| Stromal sarcoma                               |
| Leiomyosarcoma                                |
| Rhabdomyosarcoma                             |
| Leiomyoma                                    |
| Angiosarcoma                                  |
| Synovial sarcoma                              |
| Inflammatory myofibroblastic tumor            |
| Osteosarcoma                                  |
| Undifferentiated pleomorphic sarcoma          |
| Solitary fibrous tumor                        |
| Solitary fibrous tumor, malignant             |
| Hemangioma                                   |
| Granular cell tumor                          |
| **Hematolymphoid tumors**                    |
| Diffuse large B-cell lymphoma                 |
| Chronic lymphocytic lymphoma/small lymphocytic lymphoma |
| Follicular lymphoma                          |
| Mantle cell lymphoma                         |
| Acute myeloid leukemia                        |
| B lymphoblastic leukemia/lymphoma             |
| **Miscellaneous tumors**                     |
| Cystadenoma                                  |
| Nephroblastoma                               |
| Rhabdoid tumor                               |
| Germ cell tumor                              |
| Clear cell adenocarcinoma                    |
| Melanoma                                     |
| Paraganglioma                                |
| Neuroblastoma                                |
| **Metastatic tumors**                        |
the term “pseudocapsule”, which represents the abrupt transition between tumor and background prostate tissue, may be more appropriate for MRI findings [5, 45]. STUMPs usually appear as cystic masses or as masses with variable amounts of cystic and solid components [5, 46]. The cystic components have been described as bloody, mucinous, or clear fluids [40]. The solid components of STUMPs usually show gradual enhancement on DCE imaging (Figs. 12, 13), which is different from the DCE wash-out of PCa. Therefore, the PI-RADS assessment may not be applicable on mpMRI of most cases of prostatic stromal tumors.

Fig. 7 Intraductal carcinoma of the prostate in an 80-year-old man, with an elevated serum PSA level for 2 years, which was 24.46 ng/mL at the most recent measurement. a, b DWI at a b-value of 1400 s/mm² and ADC maps show a lobulated mass with restricted diffusion in the prostate (☆). c Axial T2-weighted imaging shows isointensity with an ill-defined edge of the mass (☆). d, e Axial DCE MRI at 60 s (d) and 80 s (e) after contrast injection shows no prominent enhancement of the mass (☆). Note the hemorrhagic area in the prostate gland (arrow).

Fig. 8 Mixed ductal and acinar adenocarcinoma in an 87-year-old man with dysuria for 12 months and a serum PSA level of 30.24 ng/mL. a–c Axial T2-, axial T1-, and coronal fat-suppressed T2-weighted imaging show a multilocular cyst mass occupying the prostate, periprostatic fat and bilateral seminal vesicles (black arrow on c), with heterogeneous signal intensity in cysts and multifocal solid areas (arrowheads on a), and a cyst with a thick wall and a mural nodule (arrows on a, b). d, e DWI at a b-value of 1000 s/mm² and ADC maps show inhomogenously restricted diffusion of the solid areas (arrowheads) and the thick wall (arrows). f DCE imaging shows heterogeneous enhancement of the mass.
Fig. 9 Local recurrence of urothelial carcinoma of the prostate in a 63-year-old man 1 year after completing chemotherapy. a–c Coronal fat-suppressed T2- (a) and axial T2WI (b, c) show an inhomogeneously isointense mass primarily located in the left lobe of the prostate and left seminal vesicle, invading a corner of the bladder (arrow on c). d, e DWI at a b-value of 1400 s/mm² and ADC maps show restricted diffusion in the periphery of the mass.

Fig. 10 Prostatic stromal sarcoma in a 49-year-old man with a mildly elevated serum PSA level of 7.5 ng/mL. a–c Axial fat-suppressed T1WI, ADC maps and T2WI show a mass containing solid and necrotic components (☆). The high signal intensity area on axial fat-suppressed T1WI (a) and the low signal intensity area on ADC maps (b) both suggest a hemorrhagic change (arrowhead). c Coronal fat-suppressed T2WI shows an incomplete capsule around the mass and the right seminal vesicle compressed by the mass (arrowhead). b, d ADC maps and coronal fat-suppressed T2WI show enlarged pelvic lymph nodes (arrow).

Fig. 11 Prostatic stromal sarcoma in a 41-year-old man with a normal serum PSA level of 0.784 ng/mL. a Axial T2WI shows an oval mass occupying the prostate with heterogeneous hyperintensity, an incomplete hypointense capsule and compressing the bladder (arrowhead). b, c Axial DWI and ADC maps show cystic areas occupying the majority of the mass (☆), but containing focal solid components with remarkably restricted diffusion (arrow). d Axial fat-suppressed T1WI shows the mass containing a slightly high signal intensity, which suggested a hemorrhagic change (arrow). (e–f) Axial DCE imaging (e) shows that the mass had diffuse but no enhancement of the cystic components (f, curve 2) accompanied by a gradual moderate enhancement restricted to the solid components (f, curve 1).
Fig. 12  Prostate stromal tumor of uncertain malignant potential in a 39-year-old man with a normal serum PSA level of 1.780 ng/mL.  

- **a** Axial T2WI shows a well-circumscribed nodule with heterogeneous signal and an incomplete capsule (arrowheads) located in the left PZ of the prostate and compressing the extra-prostatic tissue.  
- **b** DWI shows hypointensity, indicating no restricted diffusion of the nodule.  
- **c–f** Axial DCE imaging at 30 s (**c**), 60 s (**d**), 120 s (**e**) and 180 s (**f**) after contrast injection shows the early and gradual enhancement of the nodule.

Fig. 13  Prostate stromal tumor of uncertain malignant potential in a 33-year-old man with a normal serum PSA level of 1.080 ng/mL.  

- **a** Axial T2WI shows a 2.7-cm nodule with heterogeneous signal in the TZ of the prostate surrounded by a capsule-like hypointense rim (arrowhead).  
- **b, c** DWI and ADC maps show remarkably restricted diffusion of most of the nodule (☆).  
- **d–f** Axial DCE imaging at 30 s (**d**), 60 s (**e**) and 120 s (**f**) after contrast injection shows early and gradual enhancement of the nodule containing non-enhanced areas inside the tissue (arrow).
Prostate sarcoma
In addition to PSSs, prostate sarcomas are also mesenchymal in origin, accounting for approximately 0.1–0.2% of all primary prostate tumors [47]. Prostate sarcomas are highly aggressive tumors and usually grow rapidly. Therefore, the most common symptoms are local symptoms of the tumor’s effect on adjacent structures, such as rapid onset of urinary obstruction or a palpable mass. The serum PSA value is usually normal because of the nonepithelial origin of prostate sarcoma. At 42%, rhabdomyosarcoma is the most common prostate sarcoma, followed by leiomyosarcoma at 25%. In contrast to PCa, which primarily occurs in older people, prostate sarcoma is characterized by a wide range of onset ages. Leiomyosarcoma occurs primarily in adults between 40 and 78 years of age, while rhabdomyosarcomas are more likely to occur in children and adolescents. The principal sites of distant metastases for prostate sarcoma are the lungs, bones and liver, and bone metastases are frequently osteolytic [45], while PCa metastases primarily occur in the bone and are usually osteoblastic.

Most prostate sarcomas appear as large masses with hypointensity on T1WI and heterogeneous isointensity and hyperintensity on T2WI. Hemorrhagic and necrotic changes are common because of their high malignancy and rapid growth (Figs. 10a, b, 14a, b). Despite their locally aggressive features, prostate sarcomas often compress adjacent tissues or organs, as opposed to solely directly invading them [45], with a complete or incomplete and low T2 signal intensity for the compressible pseudocapsule (Figs. 10, 11 and 14). Prostate sarcomas are rarely confused with PCa, which usually extends by infiltrating its adjacent tissues, so it is commonly ill-defined without a capsule on T2WI. However, leiomyosarcomas and alveolar rhabdomyosarcomas are more infiltrative than other forms of prostate sarcomas, perhaps with poorly defined tumor margins on MRI [5]. Although PI-RADS is not applicable for prostate sarcomas, mpMRI helps to determine the site of origin of the tumor, its local extent, and its tissue characteristics and aids in planning surgical resection or adjunctive therapy.

Solitary fibrous tumor
A solitary fibrous tumor (SFT) is a mesenchymal tumor derived from CD34-positive mesenchymal cells and was first described in the pleura [48]. Extrapleural SFTs account for approximately 0.6% of the total incidence of soft tissue tumors [49]. Malignant SFTs of the prostate are extremely rare [50, 51].

SFTs of the prostate are slow-growing tumors usually seen among middle-aged and elderly individuals. The most frequent symptoms are obstructive urinary symptoms caused by a progressive increase in the size of the tumor [52]. The tumor dimensions are quite variable, ranging from 2 to 18 cm, with many reported to be >5 cm [53, 54]. SFTs located in the prostate may originate from the prostate or prostatic urethra [55].

SFTs generally appear as well-circumscribed masses on MRI (Fig. 15), with heterogeneous intensity on T2WI. The variable signal intensity on T2WI depends mainly on areas of collagen and fibroblasts, vascular and hypercellular areas, and the presence of degeneration [56]. Both of these appearances differ from those of PCa, which are poorly circumscribed on MRI and homogeneously hypointense on T2WI. In addition, SFTs exhibit more moderately restricted diffusion on DWI and ADC maps and more moderate enhancement on DCE imaging than PCa [57]. Therefore, although SFTs have few distinctive

![Fig. 14 Synovial sarcoma of the prostate in a 26-year-old man, with a serum prostate-specific antigen level of 1.14 ng/mL. a, b T1- and T2-weighted imaging show a heterogeneous signal mass compressing the prostatic urethra and the left lobe of the prostate, with an incomplete, low T2 signal intensity pseudocapsule (arrowheads on b) and irregular areas of hemorrhagic and necrotic changes (☆). c DWI at a b-value of 1200 s/mm² shows a high signal intensity of the solid area and low signal intensity of the cystic area of the mass (☆). d Coronal fat-suppressed T2WI shows the mass compressing the prostatic urethra and the left lobe of the prostate (arrowheads), compressing and invading the right seminal vesicle (arrow). e DCE imaging shows heterogeneous enhancement of the lobulated mass invading seminal vesicles (white arrow). Note the residual tissue of the left seminal vesicle (black arrow).](image-url)
features on mpMRI, they can be distinguished from PCa, and the PI-RADS assessment may not be suitable for use.

The characteristics of malignant extrapleural SFTs include a large tumor size (greater than 10 cm in diameter), hypercellularity, nuclear atypia, a high mitotic index (> 4 mitoses/10 high-power fields), necrosis and infiltrative margins [58]. Considering the rarity of SFTs of the prostate and the low predictability of their malignant potential [59], long-term clinical follow-up is recommended.

**Lymphoma**

Malignant lymphoma involving the prostate is a rare kind of extranodal lymphoma, and diffuse large B cell lymphoma (DLBCL) is the most frequently seen type. The prostate gland is the site of 0.1% of non-Hodgkin lymphomas (NHLs) and 0.9% of extranodal lymphomas. Primary malignant lymphoma involving the prostate, which is located in the prostate without evidence of systemic lymph node invasion by lymphoma cells, accounts for 0.09% of all prostatic malignancies [60], and is less common than secondary lymphoma. The serum PSA level of prostatic lymphoma is usually less than 4 ng/mL. In addition to LUTS, systemic symptoms of lymphoma may be present, although uncommon, including fever, chills, night sweats, and weight loss [61, 62].

Prostatic lymphomas grow rapidly and invade surrounding organs easily; therefore, they often appear as large, irregular and lobulated masses with or without invasion of neighboring organs on prostate MRIs (Fig. 16b), and the PI-RADS assessment may be used unavoidably for prostatic lymphomas. They are usually homogeneous isointense on T1WI/T2WI and present with homogeneously restricted diffusion on DWI and ADC maps (Fig. 16) because they are rarely accompanied by hemorrhage and necrosis [63]. On DWI and ADC maps, lymphomas show observably restricted diffusion as a result of the high density of lymphoma cells, their high karyoplasmic ratio, abundant extracellular microstructures and intracellular proteins. On DCE imaging, moderate enhancement of the mass may be observed [64].

**Prostatic cystadenoma**

Prostatic cystadenoma is a rare benign tumor consisting of cysts and prostatic glands. A large range for the age at the time of presentation has been reported, from 23 to 80 years, and the most frequent clinical symptoms are LUTS [65]. The serum PSA level is often, but not always, elevated, as it is expressed by the neoplastic tissue, consisting of dilated glandular structures and prostatic epithelia [66].
The typical MR futures of prostatic cystadenomas are easy to identify, and the PI-RADS assessment is not applicable. Prostatic cystadenomas can grow to large proportions, causing distinct mass effects but not invading adjacent tissues. On T2WI, prostatic cystadenomas appear as multilocular cystic lesions of high signal intensity with surrounding isointense soft tissue. Variations in T2 and T1 signal intensities are suggestive of hemorrhage or proteinaceous fluid (Fig. 17). Occasionally, the presence of fluid–fluid levels may occur [47]. ADC maps of the lesions usually show no restricted diffusion in the cysts but lower ADC values in the septa and solid components. In addition, enhancement of the septa and solid components may be observed.
Conclusions
The clinical MRI diagnostic workflow for prostatic diseases listed below is recommended when clinicians are deciding whether to use the PI-RADS assessment.

First, past relevant history and recent symptoms should be considered. Iatrogenic causes (after surgical operations or BCG therapy for urothelial carcinoma) and allergy may result in granulomatous prostatitis (including tuberculosis). In addition to nonspecific LUTS, some symptoms and signs may provide more specific information. Prostate tuberculosis may be accompanied by active tuberculosis in other organs or systems. Fever, chills, urinary frequency and urgency, suprapubic pain, and pus cells on urine examination are typical for abscesses. Systemic symptoms of lymphoma include fever, chills, night sweats, weight loss or lymphoma in other tissues. Rapid onset of urinary obstruction or a palpable mass may hint at tumors with rapid growth or invading the prostatic urethra.

Second, age and serum PSA levels should be taken into account because they are important factors in differential diagnoses. PCa and BPH tend to occur in individuals older than 50 years with elevated serum PSA levels, while serum PSA levels in patients with other tumors are usually in the normal range, except for prostatic cystadenoma because its neoplastic tissue expresses PSA. Some malignant mesenchymal tumors, such as rhabdomyosarcoma, are more common in children and adolescents with normal serum PSA levels. In addition, the serum PSA levels of granulomatous prostatitis may be elevated or normal due to the progression of or improvement in the disease.

Table 2 Primary clinical or mpMRI characteristics of prostatic abnormalities

| Prostatic abnormalities                | Primary clinical or mpMRI characteristics                                                                 |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Acinar adenocarcinoma with/without other glandular neoplasms | Age: elderly men  
PSA: sharply elevated  
PI-RADS: suitable |
| BPH                                    | Age: elderly men  
PSA: slightly elevated  
PI-RADS: suitable |
| Chronic prostatitis                    | PSA: slightly elevated  
PI-RADS: suitable |
| Benign hyperplastic nodules outside the TZ | PSA: Slightly elevated  
PI-RADS: unsuitable |
| Granulomatous prostatitis              | Past relevant history: iatrogenic causes (after surgical operations or BCG therapy for urothelial carcinoma) and allergy  
PSA: transiently elevated  
PI-RADS: unavoidable |
| Prostate tuberculosis                  | Past relevant history: BCG therapy for urothelial carcinoma  
Symptoms: active tuberculosis in other organs or systems  
PSA: transiently elevated  
PI-RADS: unsuitable |
| Abscess                                | Symptoms: fever, chills, urinary frequency and urgency, suprapubic pain, and pus cells on urine examination  
PSA: transiently elevated  
mpMRI findings: central necrosis in the interior presenting with hyperintensity on T2WI, hyperintensity on high b-value DWI, and low ADC, with rim enhancement in the exterior  
PI-RADS: unsuitable |
| Mesenchymal tumors                     | Age: younger men  
PSA: normal  
mpMRI findings: hemorrhagic, cystic or necrotic changes with complete or incomplete capsule causing distinct mass effects  
PI-RADS: unsuitable |
| Lymphoma                               | PSA: normal  
Symptoms: LUTS, systemic symptoms (including fever, chills, night sweats, and weight loss)  
PI-RADS: unavoidable |
| Prostatic cystadenoma                  | Age: large age range  
mpMRI findings: cystic lesions  
PI-RADS: unavoidable |

PSA prostate-specific antigen, PI-RADS Prostate Imaging Reporting and Data System, BPH benign prostatic hyperplasia, TZ transitional zone, BCG bacillus Calmette–Guérin, mpMRI multiparametric magnetic resonance imaging, T2WI T2-weighted imaging, DWI diffusion-weighted imaging, ADC apparent diffusion coefficient, LUTS lower urinary tract symptoms
Third, noninvasive mpMRI provides comprehensive information that is needed for preoperative diagnosis and evaluation of prostate diseases. Granulomatous prostatitis and lymphoma mimic PCa on mpMRI. BPH nodules outside the TZ are analogous to those in the TZ on mpMRI, and the size of the nodule may also increase with the progression of BPH in the TZ. Prostate abscesses demonstrate central necrosis in the interior inside presenting with hyperintensity on T2WI, hyperintensity on high b-value DWI, and low ADC, with rim enhancement in the exterior. Malignant mesenchymal tumors usually exhibit hemorrhagic, cystic or necrotic changes with complete or incomplete capsules and cause distinct mass effects.

By combining the above three steps, it is possible to decide whether to use PI-RADS assessment. PI-RADS assessments are suggested for abnormalities simulating PCa, and biopsy should be considered for PI-RADS category 4 or 5. For diseases unsuitable for PI-RADS assessment, it is important to draw a few qualitative conclusions or primarily differentiate the pathological condition if possible. However, biopsy may also be necessary for PI-RADS 1–3 lesions in patients with very high serum PSA levels. In conclusion, although the detection and staging of PCa are the most common tasks when performing prostate mpMRI and using the PI-RADS assessment, radiologists must continue to consider that not every prostate lesion is an adenocarcinoma and must have an intimate knowledge of other diseases. Past relevant history, symptoms, age, serum PSA levels, mpMRI manifestations, and the applicability of PI-RADS assessment (Table 2) should be considered to reduce unnecessary biopsy while maintaining the diagnostic sensitivity for malignant lesions.

Abbreviations
ADC: Apparent diffusion coefficient; BCG: Bacillus Calmette-Guérin; BPH: Benign prostatic hyperplasia; cPCa: Clinically significant prostate cancer; CZ: Central zone; DCE: Dynamic contrast-enhanced; DLBCL: Diffuse large B cell lymphoma; DWI: Diffusion-weighted imaging; EPE: Extraprostatic extension; IDC-P: Intraductal carcinoma of the prostate; LUTS: Lower urinary tract symptoms; mpMRI: Multiparametric magnetic resonance imaging; NHL: Non-Hodgkin lymphoma; PI-RADS: Prostate Imaging Reporting and Data System; PSA: Prostate-specific antigen; PSS: Prostatic stromal sarcoma; PZ: Peripheral zone; RP: Radical Prostatectomy; SFT: Solitary fibrous tumor; STUMP: Stromal tumor of uncertain malignant potential; T2WI: T2-weighted imaging; TURP: Transurethral resection of prostate; TZ: Transitional zone.

Authors’ contributions
CH: Writing—original draft, Conceptualization, Data curation. LZ: Data curation, Writing—original draft. XL: Data curation, Writing—original draft. SM: Conceptualization. YL: Conceptualization. XW: Writing—review & editing, Project administration, Supervision, Funding acquisition. All authors read and approved the final manuscript.

Funding
This study has received funding by the Capital Health Research and Development of Special (Grant No. 2020–2-40710).

Availability of data and materials
The data of cases in the manuscript are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The review was approved by the local Institutional Review Board, and the requirement for written consent was waived.

Consent for publication
The authors of this manuscript consent for publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Radiology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. 2 Department of Radiology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe Road, Zhengzhou Henan Province 450052, China.

Received: 28 November 2020 Accepted: 31 May 2021

Published online: 16 June 2021

References
1. Gupta RT, Spilseth B, Froemming AT (2016) How and why a generation of radiologists must be trained to accurately interpret prostate mpMRI. Abdom Radiol (NY) 41:803–804
2. Oberlin DT, Casalino DD, Miller FH, Meeks JJ (2017) Dramatic increase in the utilization of multiparametric magnetic resonance imaging for detection and management of prostate cancer. Abdom Radiol (NY) 42:1255–1258
3. Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 76:340–351
4. Woo S, Suh CH, Kim SY, Cho JY, Kim SH (2017) Diagnostic performance of prostate imaging reporting and data system version 2 for detection of prostate cancer: a systematic review and diagnostic meta-analysis. Eur Urol 72:177–188
5. Chu LC, Ross HM, Lotan TL, Macura KJ (2013) Prostatic stromal neoplasms: differential diagnosis of cystic and solid prostatic and periprostatic masses. AJR Am J Roentgenol 200:W571–W580
6. Nunziolo CD, Miano R, Trucchi A, Agrò EF, Tubaro A (2008) Finasteride for prostatic disease: an updated and comprehensive review. Expert Opin Drug Metab Toxicol 4:1561–1568
7. Bangma CH, Blijenberg BG, Schroder FH (1995) Prostate-specific antigen: its clinical use and application in screening for prostate cancer. Scand J Clin Lab Invest Suppl 221:35–44
8. Organization WH (2018) Cancer. https://www.who.int/health-topics/cancer?tab=tab_1. Accessed 3 Aug 2020
9. Bajic P, Dornbier RA, Doshi CP, Wolfe AJ, Farooq AV, Bresler L (2019) Implications of the genitourinary microbiota in prostatic disease. Curr Urol Rep 20:34
10. Voorde WMvD, Oyen RH, Poppel HPV, Wouters K, Baert LV, Lauweryns JM (1995) Peripherally localized benign hyperplastic nodules of the prostate. Mod Pathol 8:46–50
11. Oyen RH, Voorde WMvD, Poppel HPV et al (1993) Benign hyperplastic nodules that originate in the peripheral zone of the prostate gland. Radiology 189:707–711
12. Tang J, Li X, Wang N et al (2005) Correlation between hypoechoic nodules on ultrasonography and benign hyperplasia in the prostatic outer gland. J Ultrasound Med 24:483–488

13. Tang J, Yang JC, Zhang Y et al (2007) Does benign prostatic hyperplasia originate from the peripheral zone of the prostate? A preliminary study. BJU Int 100:1091–1096

14. Yang JC, Tang J, Li Y, Fei X, Shi H (2008) Contrast-enhanced transrectal ultrasound for assessing vascularization of hypoechoic BPH nodules in the transition and peripheral zones: comparison with pathological examination. Ultrasound Med Biol 34:1758–1764

15. Kumbar R, Dravid N, Nikumbh D, Patil A, Nagappa KG (2016) Clinical-pathological overview of granulomatous prostatitis: an appraisal. J Clin Diag Res 10 E020–E23

16. Crocetto F, Barone B, Luca LD, Creta M (2020) Granulomatous prostatitis: a challenging differential diagnosis to take into consideration. Future Oncol 16:805–806

17. Shukla R, Gulvani M, Kaur S (2017) Granulomatous prostatitis: clinical and histomorphologic survey of the disease in a tertiary care hospital. Prostate Int 5:29–34

18. Speights VO Jr, Brawn PN (1996) Serum prostate specific antigen levels in prostate cancer. J Urol 155:1907–1911

19. Lee S-M, Wolfe K, Acher P, Liyanage SH (2019) Multiparametric MRI findings of granulomatous prostatitis: a case report. J Clin Diag Res 10 E020–E23

20. Rais-Bahrami S, Nix JW, Turkbey B et al (2017) Clinical and multiparametric MRI signatures of granulomatous prostatitis. Abdom Radiol (NY) 42:1956–1962

21. Suzuki T, Takeuchi M, Naiki T et al (2013) MRI findings of granulomatous prostatitis developing after intravesical Bacillus Calmette-Guerin therapy. J Magn Reson Imaging 47:60–68

22. Lee SM, Wolfe K, Acher P, Liyanage SH (2019) Multiparametric MRI appearances of primary granulomatous prostatitis. Br J Radiol 92:20180075

23. Kitzing YX, Prando A, Varol C, Karczmar GS, Maclean F, Oto A (2016) Multiparametric MRI of prostatic ductal adenocarcinoma. J Magn Reson Imaging 41:1639–1645

24. Gobbi AD, Morlacco A, Valotto C, Vianello F, Zattoni F (2016) An unusual cystic presentation of ductal carcinoma of the prostate. Urologia 83:211–213

25. Matsui Y, Sugino Y, Iwamura H, Oka H, Fukushima S, Takeuchi H (2002) Ductal adenocarcinoma of the prostate associated with prostatic multi-loccular cyst. Int J Urol 9:413–415

26. Zhou J, Yang C, Li Z et al (2019) Primary urothelial carcinoma of the prostate: a rare case report. Medicine (Baltimore) 98:e14155

27. Crocetto F, Barone B, Luca LD, Creta M (2020) Granulomatous prostatitis: a challenging differential diagnosis to take into consideration. Future Oncol 16:805–806

28. Shukla R, Gulvani M, Kaur S (2017) Granulomatous prostatitis: clinical and histomorphologic survey of the disease in a tertiary care hospital. Prostate Int 5:29–34

29. Speights VO Jr, Brawn PN (1996) Serum prostate specific antigen levels in prostate cancer. J Urol 155:1907–1911

30. Lee S-M, Wolfe K, Acher P, Liyanage SH (2019) Multiparametric MRI findings of granulomatous prostatitis: a case report. J Clin Diag Res 10 E020–E23
61. Bostwick DG, Iczkowski KA, Amin MB, Discigil G, Osborne B (1998) Malignant lymphoma involving the prostate: report of 62 cases. Cancer 83:732–738
62. Chang JM, Lee HJ, Lee SE et al (2008) Unusual tumours involving the prostate: radiological–pathological findings. Br J Radiol 81:907–915
63. Feng Z-Y, Min X-D, Wang L et al (2018) MRI feature analysis of uncommon prostatic malignant tumors. Asian J Androl 20:313–315
64. Claikens B, Oyen R, Goethuys H, Boogaerts M, Baert AL (1997) Non-hodgkin's lymphoma of the prostate in a young male. Eur Radiol 7:238–240
65. Nakamura Y, Shida D, Shibayama T et al (2019) Giant multilocular prostatic cystadenoma. World J Surg Oncol 17:42
66. Olgun DC, Onal B, Mihmanli I et al (2012) Giant multilocular cystadenoma of the prostate: a rare cause of huge cystic pelvic mass. Korean J Urol 53:209–213

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.